Logo
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Ελληνικά 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Σύνδεση
Προβολή τεκμηρίου 
  •   Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Προβολή τεκμηρίου
  •   Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Προβολή τεκμηρίου
JavaScript is disabled for your browser. Some features of this site may not work without it.
Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
Όλο το DSpace
  • Κοινότητες & Συλλογές
  • Ανά ημερομηνία δημοσίευσης
  • Συγγραφείς
  • Τίτλοι
  • Λέξεις κλειδιά

How can we effectively address the paraneoplastic dermatomyositis: Diagnosis, risk factors and treatment options

Thumbnail
Συγγραφέας
Zerdes I., Tolia M., Nikolaou M., Tsoukalas N., Velentza L., Hajiioannou J., Mitsis M., Kyrgias G.
Ημερομηνία
2017
Γλώσσα
en
Λέξη-κλειδί
azathioprine
immunoglobulin
methotrexate
monoclonal antibody
prednisone
antiinflammatory agent
autoinflammatory disease
breast cancer
cancer radiotherapy
collagen disease
colonoscopy
colorectal cancer
computer assisted tomography
dermatomyositis
diabetes mellitus
disease association
drug efficacy
human
hypertension
immunosuppressive treatment
laboratory test
lung cancer
mixed connective tissue disease
nasopharynx cancer
nonhodgkin lymphoma
ovary cancer
paraneoplastic syndrome
physical examination
prostate cancer
radiation injury
Review
risk factor
systematic review
systemic sclerosis
thorax radiography
treatment response
vascular disease
clinical trial (topic)
dermatomyositis
meta analysis
neoplasm
paraneoplastic syndrome
randomized controlled trial (topic)
Anti-Inflammatory Agents
Clinical Trials as Topic
Dermatomyositis
Humans
Neoplasms
Paraneoplastic Syndromes
Prednisone
Randomized Controlled Trials as Topic
Risk Factors
Zerbinis Publications
Εμφάνιση Μεταδεδομένων
Επιτομή
Purpose: Dermatomyositis (DM) represents an auto-immune inflammatory myopathy. In this review, we analyzed the incidence of DM as a clinical manifestation highlighting the peculiar clinical and treatment characteristics of this disease when occurring in the context of different malignancies. Methods: A systematic literature review was performed based on database search in PubMed/Medline and included English articles until December 2016. Results: In up to 20% of cases DM appears as a paraneoplastic syndrome associated with multiple malignancies such as ovarian, breast, prostate, lung, nasopharyngeal and colorectal cancer, and non-Hodgkin lymphomas. It can be presented either before, in the time, or after cancer diagnosis. Systemic sclerosis and mixed connective-tissue disease represent common coinciding disorders. Particular caution should be given in the radiotherapy because the microvascular endothelial radiation damage and autoimmune inflammatory collagen vascular disease caused by DM may be additive. There is a higher risk of late toxicity in the presence of other concurrent vascular diseases, including diabetes, hypertension or administration of chemotherapy. Prednisone represents the first-line treatment option but immunosuppressive drugs such as azathioprine and methotrexate may also be incorporated in the therapeutic armamentarium especially when DM is associated with malignancy. Intravenous immunoglobulin could be a promising alternative in prednisone-resistant cases. The effectiveness of therapies with antigen-specific agents such as monoclonal antibodies is currently under investigation. Conclusions: Timely diagnosis coupled with a treatment plan focused on muscular endurance and improvement of skin lesions and other symptoms offer a favorable response to therapy along with the achievement of a higher quality of life for these patients. © 2017 Zerbinis Publications. All rights reserved.
URI
http://hdl.handle.net/11615/80969
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19735]

Related items

Showing items related by title, author, creator and subject.

  • Thumbnail

    Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG) 

    Christodoulou C., Kalogera-Fountzila A., Karavasilis V., Kouvatseas G., Papandreou C.N., Samantas E., Varaki K., Papadopoulos G., Bobos M., Rallis G., Razis E., Goudopoulou A., Kalogeras K.T., Syrigos K.N., Fountzilas G. (2017)
    Small molecules, mainly tyrosine kinase inhibitors, are currently used in various malignancies. Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has demonstrated effectiveness in brain metastases from HER2-overexpressing ...
  • Thumbnail

    Hepatocyte autotaxin expression promotes liver fibrosis and cancer 

    Kaffe E., Katsifa A., Xylourgidis N., Ninou I., Zannikou M., Harokopos V., Foka P., Dimitriadis A., Evangelou K., Moulas A.N., Georgopoulou U., Gorgoulis V.G., Dalekos G.N., Aidinis V. (2017)
    Autotaxin (ATX) is a secreted lysophospholipase D that catalyzes the production of lysophosphatidic acid (LPA), a pleiotropic growth-factor–like lysophospholipid. Increased ATX expression has been detected in various chronic ...
  • Thumbnail

    TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting 

    Fountzilas G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., Lakis S., Bobos M., Poulios C., Sotiropoulou M., Lyberopoulou A., Gogas H., Pentheroudakis G., Pectasides D., Koutras A., Christodoulou C., Papandreou C., Samantas E., Papakostas P., Kosmidis P., Bafaloukos D., Karanikiotis C., Dimopoulos M.-A., Kotoula V. (2016)
    Background: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- ...
htmlmap 

 

Πλοήγηση

Όλο το DSpaceΚοινότητες & ΣυλλογέςΑνά ημερομηνία δημοσίευσηςΣυγγραφείςΤίτλοιΛέξεις κλειδιάΑυτή η συλλογήΑνά ημερομηνία δημοσίευσηςΣυγγραφείςΤίτλοιΛέξεις κλειδιά

Ο λογαριασμός μου

ΣύνδεσηΕγγραφή (MyDSpace)
Πληροφορίες-Επικοινωνία
ΑπόθεσηΣχετικά μεΒοήθειαΕπικοινωνήστε μαζί μας
Επιλογή ΓλώσσαςΌλο το DSpace
EnglishΕλληνικά
htmlmap